TEVA PHARMACEUTICAL INDUSTRIES LTD. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Gerald M. Lieberman

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Gerald M. Lieberman”): 560,335,672 for, 133,450,043 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 81,784,469 for, 27,422,624 against, 47,616 abstained.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: Election of Directors: Prof. Varda Shalev

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Prof. Varda Shalev”): 602,030,429 for, 91,772,897 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 109,189,486 for, 17,607 against, 47,616 abstained.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Prof. Ronit Satchi-Fainaro

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Prof. Ronit Satchi-Fainaro”): 517,677,574 for, 176,129,338 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 54,491,107 for, 54,715,986 against, 47,616 abstained.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: Election of Directors: Rosemary A. Crane

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Rosemary A. Crane”): 511,812,296 for, 181,995,022 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 72,618,149 for, 36,588,944 against, 47,616 abstained.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting”): 571,822,049 for, 120,609,632 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 107,150,558 for, 2,056,112 against, 47,616 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 425 managers: 376,546,039 for, 48,421,328 against, 1,828,676 abstained, 20,699 not voted, 399,852 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To recommend, on a non-binding advisory basis, to hold a non- binding advisory vote to approve the compensation for Teva's named executive officers every one, two or three years.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 73 managers: 47,616 abstained, 102,291,087 1 year, 950,227 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 384 managers: 2,684,392 for, 20 against, 1,569,573 abstained, 20,699 not voted, 324,241,237 1 year, 4,723,382 3 year, 2,028 2 year, 220 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To appoint, Kesselman & Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2025 annual meeting of shareholders.

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“4. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2025 annual meeting of shareholders”): 731,150,255 for, 30,335,560 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “ (4) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2025 annual meeting of shareholders, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 108,807,666 for, 195,317 against, 47,616 abstained.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.